rs25487 — XRCC1 R399Q
Base excision repair scaffold protein that coordinates repair of oxidative DNA damage and single-strand breaks; the Gln variant reduces repair efficiency at the PARP-binding domain
Details
- Gene
- XRCC1
- Chromosome
- 19
- Risk allele
- A
- Protein change
- p.Arg399Gln
- Consequence
- Missense
- Inheritance
- Codominant
- Clinical
- Risk Factor
- Evidence
- Strong
- Chip coverage
- v3 v4 v5
Population Frequency
Ancestry Frequencies
Related SNPs
Category
Cancer RiskSee your personal result for XRCC1
Upload your DNA data to find out which genotype you carry and what it means for you.
Upload your DNA dataWorks with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.
XRCC1 R399Q — Your DNA Damage Repair Coordinator
Every day, your DNA sustains tens of thousands of lesions from normal
metabolism — oxidative hits from mitochondrial respiration, alkylation
from reactive metabolites, and spontaneous depurination. The
base excision repair (BER) pathway11 base excision repair (BER) pathway
The primary mechanism for repairing small, non-helix-distorting base lesions in DNA. BER handles oxidized bases (like 8-oxoguanine), deaminated bases, and single-strand breaks — the most common types of DNA damage.
is the frontline defense against this constant assault, and
XRCC122 XRCC1
X-Ray Repair Cross-Complementing group 1 — despite its name suggesting radiation repair, XRCC1 is primarily a scaffold protein for base excision repair of everyday oxidative DNA damage
is its central coordinator. XRCC1 has no enzymatic activity of its own;
instead, it serves as a molecular scaffold that physically recruits and
organizes the enzymes needed at each step of the repair process.
The rs25487 variant (R399Q) changes arginine to glutamine at position 399,
right in the
BRCT1 domain33 BRCT1 domain
BRCA1 C-terminal domain 1 — a protein-protein interaction module found in many DNA repair proteins. In XRCC1, the BRCT1 domain mediates the critical interaction with PARP-1, the enzyme that detects single-strand breaks.
that mediates the interaction with PARP-1. This single amino acid change
subtly reduces the efficiency of the entire BER assembly, with consequences
that become measurable at the population level — particularly when combined
with environmental DNA-damaging exposures.
The Mechanism
XRCC1 functions as a multi-domain scaffold with distinct binding sites for
each BER enzyme.
PARP-144 PARP-1
Poly(ADP-ribose) polymerase 1 — the "damage sensor" that detects single-strand breaks and signals for repair by attaching poly(ADP-ribose) chains to nearby proteins, including itself
first detects the strand break and synthesizes poly(ADP-ribose) chains
that recruit XRCC1 to the damage site. XRCC1 then sequentially coordinates
DNA polymerase beta55 DNA polymerase beta
The gap-filling polymerase that inserts the correct nucleotide after the damaged base has been removed,
DNA ligase III66 DNA ligase III
Seals the remaining nick in the sugar-phosphate backbone to complete the repair,
and
polynucleotide kinase77 polynucleotide kinase
Processes damaged DNA termini so they can be properly joined.
The Arg399Gln substitution occurs within the BRCT1 domain responsible for PARP-1 binding. The glutamine residue alters the electrostatic properties of this interaction surface, reducing the affinity between XRCC1 and PARP-1. This does not abolish repair — it slows the kinetics of scaffold assembly. Under normal conditions, the delay may be inconsequential. Under high oxidative stress or heavy carcinogen exposure, the reduced repair throughput allows more DNA damage to persist through cell division, increasing mutagenesis.
Functional studies confirm the consequence:
Lunn et al.88 Lunn et al.
Lunn RM et al. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res, 1999
found that individuals carrying the 399Gln allele had significantly higher
levels of aflatoxin B1-DNA adducts and elevated frequencies of glycophorin A
somatic mutations — both direct biomarkers of reduced DNA repair capacity
in vivo.
The Evidence
Lung cancer. A
meta-analysis of 8 studies in Chinese populations99 meta-analysis of 8 studies in Chinese populations
Zheng H et al. XRCC1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. Lung Cancer, 2009
(2,861 cases, 2,783 controls) found the combined Arg/Gln+Gln/Gln genotype
borderline significantly associated with lung cancer risk (OR 1.16, 95% CI
1.00-1.36). The gene-smoking interaction is biologically coherent: tobacco
smoke generates massive oxidative DNA damage and bulky adducts, overwhelming
BER capacity that is already reduced by the variant.
A
systematic review of XRCC1 polymorphism data1010 systematic review of XRCC1 polymorphism data
Ginsberg G et al. Polymorphism in the DNA repair enzyme XRCC1: utility of current database and implications for human health risk assessment. Mutat Res, 2011
found that Gln/Gln homozygotes have 3-4-fold diminished capacity to remove
DNA adducts and oxidized DNA damage, providing a mechanistic basis for the
observed gene-carcinogen exposure interactions.
Gastric cancer. A
HuGE review and meta-analysis of 12 studies1111 HuGE review and meta-analysis of 12 studies
Xue H et al. XRCC1 genetic polymorphisms and gastric cancer risk: A HuGE review and meta-analysis. Am J Epidemiol, 2011
found a pooled OR of 1.04 (95% CI 0.90-1.20) for the Arg399Gln variant and
gastric cancer, with no statistically significant overall association. The
interaction with
Helicobacter pylori1212 Helicobacter pylori
A bacterium that colonizes the stomach lining, causing chronic inflammation and oxidative stress. H. pylori infection combined with impaired BER may compound gastric cancer risk.
infection is suspected but not yet fully quantified in large studies.
Bladder cancer. A
meta-analysis of 24 case-control studies1313 meta-analysis of 24 case-control studies
Yang D et al. Association of XRCC1 Arg399Gln polymorphism with bladder cancer susceptibility: a meta-analysis. Gene, 2014
found a modest association in heterozygote carriers (AG vs GG: OR 1.11,
95% CI 1.02-1.21), with stronger effects in non-Asian populations. Bladder
epithelium is chronically exposed to urinary carcinogens and their
metabolites, making efficient BER particularly important in this tissue.
Overall cancer risk. A
meta-analysis of 38 case-control studies1414 meta-analysis of 38 case-control studies
Hu Z et al. XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev, 2005
(11,957 cases, 14,174 controls) found no significant overall association
for the Arg399Gln variant (Gln/Gln OR 1.01, 95% CI 0.90-1.14), with
notable heterogeneity by cancer site. The effect sizes for individual
cancer types are modest (OR approximately 1.0-1.2), consistent with a
common variant that modestly shifts lifetime cancer probability in specific
tissues rather than deterministically causing disease.
Practical Actions
The actionable insight from XRCC1 R399Q centers on supporting the BER
pathway biochemically. PARP-1, the enzyme whose interaction with XRCC1 is
impaired by this variant, consumes
NAD+1515 NAD+
Nicotinamide adenine dinucleotide — an essential coenzyme that PARP-1 cleaves to generate the poly(ADP-ribose) chains used in damage signaling. Heavy DNA damage can deplete cellular NAD+ pools.
as its substrate. Under conditions of high DNA damage, PARP-1 activity
can substantially deplete cellular NAD+ reserves. For carriers of the
399Gln variant, where PARP-1 recruitment is already suboptimal, ensuring
adequate NAD+ precursor availability becomes especially relevant.
Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are direct NAD+ precursors that bypass the rate-limiting step in the salvage pathway. Supporting NAD+ levels ensures PARP-1 has sufficient substrate to generate the damage-signaling chains that recruit XRCC1 to repair sites.
Additionally, reducing the burden of oxidative DNA damage through targeted antioxidant strategies — particularly compounds shown to reduce 8-oxoguanine formation — can partially compensate for slower repair kinetics. Sulforaphane from cruciferous vegetables upregulates the Nrf2 pathway, which increases expression of multiple antioxidant and DNA repair enzymes.
Interactions
XRCC1 R399Q interacts with other DNA repair pathway variants. The most direct interaction is with rs1799782 (XRCC1 R194W), another variant in the same gene located in the linker region between the N-terminal and BRCT1 domains. Compound heterozygosity for both R399Q and R194W has been associated with further reduced repair capacity compared to either variant alone, though large studies quantifying the combined effect are limited.
Interaction with rs1799793 (ERCC2 D312N) is biologically plausible: ERCC2/XPD participates in nucleotide excision repair of bulky DNA adducts, a complementary pathway to BER. When both BER (via XRCC1) and NER (via ERCC2) are impaired, the overall DNA repair capacity is more substantially compromised. Several studies have reported elevated cancer risk when variant alleles at both loci co-occur.
The interaction with NBS1 rs1805794 (E185Q) follows similar logic — NBS1 participates in double-strand break sensing via the MRN complex. Reduced function in both single-strand (XRCC1) and double-strand (NBS1) repair pathways could compound genomic instability.
Nutrient Interactions
Genotype Interpretations
What each possible genotype means for this variant:
Normal XRCC1 scaffold function with efficient base excision repair
You carry two copies of the G allele (Arg/Arg), encoding the wild-type XRCC1 protein with arginine at position 399. Your BRCT1 domain has normal affinity for PARP-1, allowing efficient assembly of the base excision repair complex at DNA damage sites. About 40% of people of European descent share this genotype, though it is more common in African populations (approximately 76%).
One copy of the Gln399 variant — modestly reduced BER scaffold efficiency
The heterozygous state produces both Arg399 and Gln399 forms of XRCC1. The Gln399 protein has subtly reduced PARP-1 binding affinity in the BRCT1 domain, slowing the assembly of the BER repair complex. Under normal conditions, the wild-type copy provides sufficient scaffold function. The clinical effect becomes measurable primarily under conditions of heavy oxidative or carcinogenic stress — tobacco smoke exposure, chronic inflammation, or occupational carcinogen exposure.
Population studies show modest and inconsistent associations across cancer types. Meta-analyses find borderline lung cancer associations in Asian populations (combined variant genotypes OR ~1.16) and modest bladder cancer associations in heterozygotes (OR ~1.11 in non-Asian populations). Effect sizes are small and shift lifetime probability rather than determine outcomes.
Two copies of the Gln399 variant — meaningfully reduced BER scaffold efficiency
With both copies carrying Gln399, your entire XRCC1 pool has reduced PARP-1 binding affinity in the BRCT1 domain. Functional biomarker studies show that Gln/Gln carriers accumulate higher levels of DNA adducts (aflatoxin B1-DNA adducts) and somatic mutations (glycophorin A variants) compared to Arg/Arg carriers, confirming reduced in vivo DNA repair capacity.
The clinical impact is most evident under conditions of high DNA damage load. The gene-smoking interaction is the best documented: tobacco smoke generates both oxidative lesions and bulky adducts at rates that overwhelm BER capacity more quickly when the XRCC1 scaffold is impaired. Similar logic applies to chronic H. pylori gastritis (gastric cancer) and urinary carcinogen exposure (bladder cancer).
It is important to frame this proportionately: the effect sizes across published meta-analyses are modest (OR approximately 1.0-1.2 depending on cancer site), and this variant shifts lifetime probability rather than determining disease. Millions of Gln/Gln carriers live cancer-free lives. The variant becomes most relevant when combined with modifiable environmental exposures.
Key References
Zheng et al. 2009 — meta-analysis of 8 lung cancer studies in Chinese populations (2,861 cases, 2,783 controls) found borderline significant association between Arg/Gln+Gln/Gln and lung cancer risk (OR 1.16, 95% CI 1.00-1.36), with stronger effects in smokers
Xue et al. 2011 — HuGE review and meta-analysis of 12 studies on XRCC1 Arg399Gln and gastric cancer risk; pooled OR 1.04 (95% CI 0.90-1.20), with subgroup findings pointing to Helicobacter pylori interaction
Yang et al. 2014 — meta-analysis of 24 case-control studies finding XRCC1 Arg399Gln modestly associated with bladder cancer risk in heterozygotes (AG vs GG: OR 1.11, 95% CI 1.02-1.21), especially in non-Asian populations
Hu et al. 2005 — meta-analysis of 38 case-control studies (11,957 cases, 14,174 controls) on XRCC1 polymorphisms and overall cancer risk; Gln/Gln homozygote OR 1.01 (95% CI 0.90-1.14) for overall cancer, with heterogeneity by cancer type
Lunn et al. 1999 — functional study demonstrating XRCC1 399Gln associated with higher levels of aflatoxin B1-DNA adducts and glycophorin A somatic mutations, indicating reduced DNA repair capacity
Ginsberg et al. 2011 — systematic database review of XRCC1 polymorphisms and health risk; Gln/Gln homozygotes show 3-4-fold diminished capacity to remove DNA adducts and oxidized DNA damage compared to Arg/Arg carriers